Mutation rates govern the introduction of genetic variation and influence evolutionary trajectories, disease susceptibility and species diversity. Rates are shaped by a balance between DNA damage, ...

In a study published in Current Biology on August 14, Prof. Miao Wei's team at the Institute of Hydrobiology (IHB) of the Chinese Academy of Sciences and Prof. Zhang Jianzhi's team at the University ...

A new technique, TF-High-Evolutionary (TF-HighEvo), allows large-scale assessment of de-novo mutations in multicellular organisms. Developed in collaboration with researchers from the European ...

Single-nucleotide mutation maps and simulations indicate that mutation bias and GC-biased gene conversion largely shape nucleotide composition near human transcription start sites.

This mutation rate dictates how quickly species can adapt to changing environments. Supported by a combined $2.08 million in total NSF funding across partner institutions, the multi-institutional ...

A new study from deCODE genetics uses pedigrees and sequence data from 64,806 Icelanders to shed light on the rate and nature of mutations in mitochondrial DNA (mtDNA) and the peculiar dynamics of its ...

Mice pups conceived with in vitro fertilization (IVF) in the lab have slightly increased rates of DNA errors, or mutations, compared to pups conceived naturally, a new study on artificial reproductive ...

The William H. Foege Genome Sciences Building at the University of Washington School of Medicine in Seattle contains laboratories, sequencers, computational facilities, and other resources for ...

A new study by scientists at City of Hope® and TGen, part of City of Hope, found surprisingly large differences in the number of mutations present in organs of healthy individuals. Some study ...

A new study by scientists at City of Hope ® and TGen, part of City of Hope, found surprisingly large differences in the number of mutations present in organs of healthy individuals. Some study ...

This retrospective, observational study included patients 18 years or older at ER+/HER2– metastatic breast cancer diagnosis who initiated first-line therapy with aromatase inhibitors (AI) or selective ...